Dupont De Nemours Inc (DD)
Fair ValueFundamental
57
Price
$129.89
Market Cap
$17.68B
Part 1 · What the company is worth
Overview
DuPont de Nemours, Inc. provides technology-based materials and solutions in the United States, Canada, the Asia Pacific, Latin America, Europe, the Middle East, and Africa. It operates through two segments, Healthcare & Water Technologies and Diversified Industrials. The company offers specialty components for medical devices, packaging and garments, and protective suits under the brand TYVEK; provides water filtration and separation solutions, including elements, modules, and systems serving primarily industrial wastewater and energy markets, municipal and desalination applications, and life sciences and specialty sectors. It also offers AMBERLITE ion exchange resins, FILMTEC reverse osmosis and nanofiltration elements, and INGE and ITEGRATEC ultrafiltration modules. In addition, the company offers engineered products and integrated solutions for the non-residential, residential, and repair-and-remodel construction markets, includes TYVEK house wrap, STYROFOAM insulation, and CORIAN solid surface. Further, it engages in the design and production of engineered components, systems, and process solutions used in OEM and operational applications, such as automotive, aerospace, printing, and packaging. Additionally, the company offers Vespel shapes and parts, MOLYKOTE specialty lubricants, BETAFORCE and BETASEAL structural adhesives, and Cyrel flexographic printing plates. The company was formerly known as DowDuPont Inc. and changed its name to DuPont de Nemours, Inc. in June 2019. DuPont de Nemours, Inc. was incorporated in 2015 and is headquartered in Wilmington, Delaware.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users
3M sells protective garments and respiratory gear, medical-grade materials and filtration products to the same industrial, healthcare and safety buyers DuPont serves with Tyvek, Nomex and its medical packaging lines.
Toray is the main alternative supplier of reverse-osmosis and ultrafiltration membranes for desalination and municipal water plants, the market DuPont serves with its FilmTec membranes, and also competes in high-performance fibres.
Spun off from Honeywell in October 2025, Solstice sells Spectra protective fibre against DuPont's Kevlar in body armour and ropes, and Aclar barrier films against DuPont's healthcare packaging for pharmaceuticals and medical devices.
Teijin's Twaron and Technora para-aramid fibres go head to head with DuPont's Kevlar in ballistic protection, tyre reinforcement and friction materials, and both also supply polymers to medical customers.
Through its Hydranautics unit Nitto Denko builds reverse-osmosis and nanofiltration elements for the same desalination, industrial and municipal water projects DuPont's Water Solutions business bids for.
Saint-Gobain competes with DuPont twice over: its Life Sciences arm supplies silicone tubing and single-use components to biopharma customers alongside DuPont's Liveo line, while its building-materials business sells insulation and weather barriers against Tyvek and Styrofoam.
Balance Sheet & Liquidity
Revenue
$6.99B
Trailing 12 months (through 6/30/2026)
Net Income
$55M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$227M
Total Equity
$13.92B
Total Liabilities
$7.47B
Current Ratio
2.43
Interest Coverage
-
Debt/EBITDA
1.97
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$146.31
Current Price
$129.89
Margin of Safety
+11.2%
Fair Value Range
$96.07 - $196.56
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
152.81
ROE
-5.6%
P/B Ratio
1.27
P/FCF
24.99
Gross Margin
35.1%
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
8.8%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (14)
- Gross Margin 35.1%
- P/FCF 24.99
- P/B Ratio 1.27
- Debt/Equity ratio
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- DCF valuation (Undervalued)
- Analyst Consensus 85% Buy
- Earnings Surprise avg 4.3%
- Earnings Quality (OCF/NI) 18.93
- Share Dilution 0.1%
- Net Margin Trend 0.8% vs -2.9%
- Piotroski F-Score 6/9
Failed (8)
- EPS shows upward trend
- Price CAGR 2.19%
- CapEx intensity
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- ROE 0.3%
- Revenue Growth 5Y -9.3%
Unavailable (5)
- ROIC NaN%
- Dividend Payout NaN%
- Operating Margin NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Share count is stable
Institutional Holdings
No institutional filings reported for this company.
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Ms. Lori D. Koch | CEO & Director | 50 |
| Ms. Antonella B. Franzen | Senior VP & CFO | 49 |
| Mr. Erik T. Hoover J.D. | Senior VP & General Counsel | 51 |
| Mr. Christopher P. Raia | Chief Human Resources Officer | 55 |
| Mr. Jeroen Bloemhard | President of Healthcare & Water Technologies | 56 |
| Mr. David Koch | Chief Operations & Engineering Officer | - |
| Ms. Madeleine G. Barber | VP of Tax, Controller & Chief Accounting Officer | 61 |
| Mr. Marty DeGroot | Chief Technology Officer | - |
| Mr. Matthew S. Abbott | SVP, Chief Information Officer & Chief Procurement Officer | 48 |
| Ann Giancristoforo | VP of Investor Relations, Corporate FP&A, Strategic Finance | - |
Audit Risk
8
Board Risk
7
Compensation Risk
5
Shareholder Rights Risk
2
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-17
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-04
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-09-10
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for DD, sourced from Markets Gazette.
- 4/9/2026NEGATIVEWhat's Going On With DuPont Stock Thursday?
DuPont de Nemours, Inc. (DD) experienced a premarket decline, reflecting a broader softening in market risk appetite. While the article does not provide specific financial figures or catalysts, the downward price movement suggests investor caution. Traders will be monitoring key support levels and technical indicators for potential entry or exit points. The current market sentiment indicates a short-term bearish bias for DuPont stock, potentially influenced by macroeconomic factors or sector-specific headwinds.
- 3/9/2026NEGATIVEGoldman-Led Lenders Brace for Loss on Arclin Debt as Demand Cools
Goldman Sachs-led lenders are anticipating losses on debt financing for Arclin Inc.'s acquisition of DuPont's Aramids business. Investors have shied away from the deal due to concerns over the chemical industry's volatility and demand cooling. This situation suggests potential financial distress for Arclin and could impact the value of the acquired Aramids business, indirectly affecting DuPont's sale proceeds and reputation in future divestitures. The reluctance of lenders and investors highlights significant headwinds for the sector.
- 3/4/2026NEUTRALGoldman Further Sweetens Terms on Loan for DuPont Unit’s Sale
Goldman Sachs has further sweetened terms on a downsized $1.25 billion financing package for Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. This move, despite the reduced financing amount, underscores ongoing struggles in the leveraged loan market. For investors, it signals a tight credit environment for complex M&A deals, potentially impacting valuations of similar transactions and companies' ability to fund strategic acquisitions through debt.
- 3/4/2026NEGATIVEGoldman-Led Buyout Loan for DuPont Unit Struggles to Find Buyers
The sale of risky debt is becoming increasingly challenging, as evidenced by the loan offering tied to Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business, backed by Goldman Sachs. The approximately $1.1 billion transaction is struggling to find buyers due to adverse market conditions for high-yield debt. This stalemate signals a growing risk aversion among investors, which could negatively impact future financing operations and valuations of companies reliant on this type of leverage. For DuPont, this might mean a revision of divestment plans or accepting less favorable terms.
- 2/20/2026NEUTRALGoldman Weighs Sweeter Terms on Loan Tied to DuPont Unit Sale
Goldman Sachs is considering improving terms on a $1.73 billion loan tied to Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. This is a financing activity news, not directly impacting DuPont's stock value.
via Markets Gazette